Bragar Eagel & Squire, P.C. is investigating potential claims on behalf
of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investors concerning whether
the company’s officers and board of directors violated the federal
securities laws.
On January 15, 2016, the U.S. Food and Drug Administration published a
report concerning Sarepta’s pending drug application stating that “we
cannot approve drugs for which substantial evidence of effectiveness has
not been established.”
If you purchased Sarepta securities, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters
please contact J. Brandon Walker, Esq. by email at investigations@bespc.com,
or telephone at (212) 355-4648, or by filling
out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating
in commercial and securities litigation. For additional information,
please go to www.bespc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160126006662/en/
Copyright Business Wire 2016